{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T01:47:52Z","timestamp":1773798472068,"version":"3.50.1"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[1996,8,1]],"date-time":"1996-08-01T00:00:00Z","timestamp":838857600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Pharmacokinetics and Biopharmaceutics"],"published-print":{"date-parts":[[1996,8]]},"DOI":"10.1007\/bf02353516","type":"journal-article","created":{"date-parts":[[2006,4,6]],"date-time":"2006-04-06T21:01:44Z","timestamp":1144357304000},"page":"327-348","source":"Crossref","is-referenced-by-count":8,"title":["Pharmacodynamic analysis of contractile potentiation by cholinesterase inhibitors in rats"],"prefix":"10.1007","volume":"24","author":[{"given":"Koujirou","family":"Yamamoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasufumi","family":"Sawada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuji","family":"Iga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[1996,9,17]]},"reference":[{"key":"BF02353516_CR1","first-page":"393","volume":"26","author":"R. D. N. Birtley","year":"1966","unstructured":"R. D. N. Birtley, J. B. Roberts, B. H. Thomas, and A. Wilson. Excretion and metabolism of14C-pyridostigmine in the rate.Br. J. Pharmacol. 26:393\u2013402 (1966).","journal-title":"Br. J. Pharmacol."},{"key":"BF02353516_CR2","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/j.1476-5381.1968.tb07064.x","volume":"34","author":"M. A. Husain","year":"1968","unstructured":"M. A. Husain, J. B. Roberts, B. H. Thomas, and A. Wilson. The excretion and metabolism of oral14C-pyridostigmine in the rat.Br. J. Pharmacol. 34:445\u2013450 (1968).","journal-title":"Br. J. Pharmacol."},{"key":"BF02353516_CR3","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/jps.2600800414","volume":"80","author":"T. Taylor","year":"1991","unstructured":"T. Taylor, D. R. Hawkins, T. J. Forrest, and H. Chung. Pharmacokinetics of pyridostigmine in dogs.J. Pharm. Sci. 80:353\u2013356 (1991).","journal-title":"J. Pharm. Sci."},{"key":"BF02353516_CR4","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/cpt1977212187","volume":"21","author":"T. N. Calvey","year":"1977","unstructured":"T. N. Calvey and K. Chan. Plasma pyridostigmine levels in patients with myasthenia gravis.Clin. Pharmacol. Ther. 21:187\u2013193 (1977).","journal-title":"Clin. Pharmacol. Ther."},{"key":"BF02353516_CR5","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1212\/WNL.31.2.145","volume":"31","author":"M. C. White","year":"1981","unstructured":"M. C. White, P. D. Silva, and C. W. H. Havard. Plasma pyridostigmine levels in myasthenia gravis.Neurology 31:145\u2013150 (1981).","journal-title":"Neurology"},{"key":"BF02353516_CR6","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1212\/WNL.34.8.1020","volume":"34","author":"P. S. S\u00f8rensen","year":"1984","unstructured":"P. S. S\u00f8rensen, H. Flachs, M. L. Friis, E. F. Hvidberg, and O. B. Paulson. Steady state kinetics of pyridostigmine in myasthenia gravis.Neurology 34:1020\u20131024 (1984).","journal-title":"Neurology"},{"key":"BF02353516_CR7","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1212\/WNL.26.6.536","volume":"26","author":"S. L. Cohan","year":"1976","unstructured":"S. L. Cohan, J. L. W. Pohlmann, J. Mikszewski, and D. S. O'Dohherty. The pharmacokinetics of pyridostigmine.Neurology 26:536\u2013539 (1976).","journal-title":"Neurology"},{"key":"BF02353516_CR8","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/clpt.1985.78","volume":"37","author":"U. Breyer-Pfaff","year":"1985","unstructured":"U. Breyer-Pfaff, U. Maier, A. M. Brinkmann, and F. Schumm. Pyridostigmine kinetics in healthy subjects and patients with myasthenia gravis.Clin. Pharmacol. Ther. 37:495\u2013501 (1985).","journal-title":"Clin. Pharmacol. Ther."},{"key":"BF02353516_CR9","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/BF00636797","volume":"18","author":"S.-M. Aquilonius","year":"1980","unstructured":"S.-M. Aquilonius, S.-\u00c5. Eckern\u00e4s, P. Hartvig, B. Lindstr\u00f6m, and P. O. Osterman Pharmacokinetics and oral bioavailability of pyridostigmine in man.Eur. J. Clin. Pharmacol. 18:423\u2013423 (1980).","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"BF02353516_CR10","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1212\/WNL.27.3.299","volume":"27","author":"S. L. Cohan","year":"1977","unstructured":"S. L. Cohan, K. L. Dretchen, and A. Neal. Malabsorption of pyridostigmine in patients with myasthenia gravis.Neurology 27:299\u2013301 (1977).","journal-title":"Neurology"},{"key":"BF02353516_CR11","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/cpt1972133393","volume":"13","author":"S. M. Somani","year":"1972","unstructured":"S. M. Somani, J. B. Roberts, and A. Wilson. Pyridostigmine metabolism in man.Clin. Pharmacol. Ther. 13:393\u2013399 (1972).","journal-title":"Clin. Pharmacol. Ther."},{"key":"BF02353516_CR12","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/j.1365-2125.1982.tb02031.x","volume":"14","author":"L.-I. Hardess","year":"1982","unstructured":"L.-I. Hardess, B. Lindstr\u00f6m, G. L\u00f6nnerholm, and R. O. Osterman. Pyridostigmine in human breast milk.Br. J. Clin. Pharmacol. 14:565\u2013567 (1982).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"BF02353516_CR13","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1038\/2001330a0","volume":"200","author":"J. B. Roberts","year":"1963","unstructured":"J. B. Roberts, B. H. Thomas, and A. Wilson. Excretion of neostigmine labeled with carbon-14 in urine.Nature 200:1330 (1963).","journal-title":"Nature"},{"key":"BF02353516_CR14","first-page":"234","volume":"25","author":"J. B. Roberts","year":"1965","unstructured":"J. B. Roberts, B. H. Thomas, and A. Wilson. Distribution and excretion of [14C]-neostigmine in the rat and hen.Br. J. Pharmacol. 25:234\u2013242 (1965).","journal-title":"Br. J. Pharmacol."},{"key":"BF02353516_CR15","first-page":"763","volume":"25","author":"J. B. Roberts","year":"1965","unstructured":"J. B. Roberts, B. H. Thomas, and A. Wilson. Metabolism of [14C]-neostigmine in the rat.Br. J. Pharmacol. 25:763\u2013770 (1965).","journal-title":"Br. J. Pharmacol."},{"key":"BF02353516_CR16","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/0006-2952(66)90112-2","volume":"15","author":"J. B. Roberts","year":"1966","unstructured":"J. B. Roberts, B. H. Thomas, and A. Wilson. Excretion and metabolism of oral14C-neostigmine in the rat.Biochem. Pharmacol. 15:71\u201375 (1966).","journal-title":"Biochem. Pharmacol."},{"key":"BF02353516_CR17","first-page":"617","volume":"18","author":"P. T. Nowell","year":"1962","unstructured":"P. T. Nowell, C. A. Scott, and A. Wilson. Determination of neostigmine and pyridostigmine in the urine of patients with myasthenia gravis.Br. J. Pharmacol. 18:617\u2013624 (1962).","journal-title":"Br. J. Pharmacol."},{"key":"BF02353516_CR18","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/BF00558442","volume":"15","author":"S.-M. Aquilonius","year":"1979","unstructured":"S.-M. Aquilonius, S.-\u00c5. Eckern\u00e4s, P. Hartvig, J. Hultman, B. Lindstr\u00f6m, and P. O. Osterman. Pharmacokinetic study of neostigmine in man using gas chromatographymass spectrometry.Eur. J. Clin. Pharmacol. 15:367\u2013371 (1979).","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"BF02353516_CR19","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/j.1476-5381.1972.tb07290.x","volume":"44","author":"D. J. Back","year":"1972","unstructured":"D. J. Back and T. N. Calvey. Excretion of14C-edrophonium and its metabolites in bile: The role of the liver cell and the peribiliary vascular plexus.Br. J. Pharmacol. 44:534\u2013543 (1972).","journal-title":"Br. J. Pharmacol."},{"key":"BF02353516_CR20","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1476-5381.1972.tb06882.x","volume":"46","author":"D. J. Back","year":"1972","unstructured":"D. J. Back and T. N. Calvey. The removal of14C-edrophonium from the circulation.Br. J. Pharmacol. 46:355\u2013357 (1972).","journal-title":"Br. J. Pharmacol."},{"key":"BF02353516_CR21","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1476-5381.1976.tb06963.x","volume":"56","author":"H. E. Barber","year":"1976","unstructured":"H. E. Barber, T. N. Calvey, K. T. Muir, and K. Taylor. The effect of edrophonium on erythrocyte acetylcholinesterase and neuromuscular function in the rate.Br. J. Pharmacol. 56:93\u201399 (1976).","journal-title":"Br. J. Pharmacol."},{"key":"BF02353516_CR22","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1002\/cpt1976196813","volume":"19","author":"T. N. Calvey","year":"1976","unstructured":"T. N. Calvey, N. E. Willians, K. T. Muir, and H. E. Barber. Plasma concentration of edrophonium in man.Clin. Pharmacol. Ther. 19:813\u2013820 (1976).","journal-title":"Clin. Pharmacol. Ther."},{"key":"BF02353516_CR23","doi-asserted-by":"crossref","first-page":"236","DOI":"10.2165\/00003088-198611030-00005","volume":"11","author":"S.-M. Aquilonius","year":"1986","unstructured":"S.-M. Aquilonius and P. Hartvig. Clinical pharmacokinetics of cholinesterase inhibitors.Clin. Pharmacokin. 11:236\u2013249 (1986).","journal-title":"Clin. Pharmacokin."},{"key":"BF02353516_CR24","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/0378-4347(87)80426-7","volume":"421","author":"C. Tharasse-Bloch","year":"1987","unstructured":"C. Tharasse-Bloch, C. Chabenat, P. Boucly, and J. Marchand. Determination of ambenonium chloride in serum by reversed-phase ion-pair liquid chromatography.J. Chromatog. 421:407\u2013411 (1987).","journal-title":"J. Chromatog."},{"key":"BF02353516_CR25","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0378-4347(00)80595-2","volume":"433","author":"K. Yamamoto","year":"1988","unstructured":"K. Yamamoto, Y. Kohda, Y. Saitoh, and F. Nakagawa. Determination of ambenonium in biological samples by reversed-phase ion-pair liquid chromatography.J. Chromatog. 433:167\u2013176 (1988).","journal-title":"J. Chromatog."},{"key":"BF02353516_CR26","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0378-4347(00)82587-6","volume":"496","author":"K. Ohtsubo","year":"1989","unstructured":"K. Ohtsubo, S. Higuchi, and T. Aoyama. Sensitive determination of ambenonium chloride in serum from patients with myasthenia gravis using ion-exchange resin extraction and reversed-phase ion-pair chromatography.J. Chromatog. 496:397\u2013406 (1989).","journal-title":"J. Chromatog."},{"key":"BF02353516_CR27","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1248\/bpb.16.280","volume":"16","author":"K. Yamamoto","year":"1993","unstructured":"K. Yamamoto, Y. Sawada, and T. Iga. Sensitive determination of ambenonium in plasma using inhibitory activity to acetylcholinesterase.Biol. Pharm. Bull. 16:280\u2013283 (1993).","journal-title":"Biol. Pharm. Bull."},{"key":"BF02353516_CR28","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/bdd.2510120807","volume":"12","author":"K. Yamamoto","year":"1991","unstructured":"K. Yamamoto, Y. Kohda, Y. Sawada, and T. Iga. Pharmacokinetics of ambenonium, a reversible cholinesterase inhibitor, in rats.Biopharm. Drug Dispos. 12:613\u2013625 (1991).","journal-title":"Biopharm. Drug Dispos."},{"key":"BF02353516_CR29","first-page":"257","volume":"39","author":"C. Tharasse-Bloch","year":"1989","unstructured":"C. Tharasse-Bloch, C. Chabenat, P. Boucly, F. Boismare, and J. Marchand. Pharmacokinetics of ambenonium chloride in dogs after intravenous and oral administration.Arzeneim. Forsch. 39:257\u2013258 (1989).","journal-title":"Arzeneim. Forsch."},{"key":"BF02353516_CR30","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/BF03189975","volume":"16","author":"C. Tharasse-Bloch","year":"1991","unstructured":"C. Tharasse-Bloch, C. Chabenat, P. Boucly, J. Marchand, D. Elkharrat, C. Boucly-Goester, and P. Gajdos. Pharmacokinetic studies of ambenonium chloride in patients with myasthenia gravis.Eur. J. Drug Metab. Pharmacokin. 16:299\u2013303 (1991).","journal-title":"Eur. J. Drug Metab. Pharmacokin."},{"key":"BF02353516_CR31","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/BF00280120","volume":"42","author":"K. Ohtsubo","year":"1992","unstructured":"K. Ohtsubo, N. Fujii, S. Higuchi, T. Aoyama, I. Goto, and T. Tatsuhara. Influence of food on serum ambenonium concentration in patients with myasthenia gravis.Eur. J. Clin. Pharmacol. 42:371\u2013374 (1992).","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"BF02353516_CR32","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1002\/cpt1977225part1596","volume":"22","author":"K. Chan","year":"1978","unstructured":"K. Chan and T. N. Calvey. Plasma concentration of pyridostigmine and effects in myasthenia gravis.Clin. Pharmacol. Ther. 22:596\u2013601 (1978).","journal-title":"Clin. Pharmacol. Ther."},{"key":"BF02353516_CR33","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1136\/jnnp.44.12.1141","volume":"44","author":"S. C. Davison","year":"1981","unstructured":"S. C. Davison, N. M. Hyman, A. Dehghan, and K. Chan. The relationship of plasma levels of pyridostigmine to clinical effect in patients with myasthenia gravis.J. Neurol. Neurosurg. Psychiat. 44:1141\u20131145 (1981).","journal-title":"J. Neurol. Neurosurg. Psychiat."},{"key":"BF02353516_CR34","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1136\/jnnp.46.10.929","volume":"46","author":"S.-M. Aquilonius","year":"1983","unstructured":"S.-M. Aquilonius, S.-\u00c5. Eckern\u00e4s, P. Hartvig, B. Lindstr\u00f6m, and P. O. Osterman. Clinical pharmacology of pyridostigmine and neostigmine in patients with myasthenia gravis.J. Neurol. Neurosurg. Psychiat. 46:929\u2013935 (1983).","journal-title":"J. Neurol. Neurosurg. Psychiat."},{"key":"BF02353516_CR35","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1248\/bpb.17.944","volume":"17","author":"K. Yamamoto","year":"1994","unstructured":"K. Yamamoto, Y. Sawada, and T. Iga. Appearance of tolerance in increase of contractile muscle tension by ambenonium in rats.Biol. Pharm. Bull. 17:944\u2013947 (1994).","journal-title":"Biol. Pharm. Bull."},{"key":"BF02353516_CR36","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/0028-3908(75)90106-9","volume":"14","author":"M. Kordas","year":"1975","unstructured":"M. Kordas, M. Brzin, and Z. A. Majcen. A comparison of the effect of cholinesterase inhibitors on end-plate current and on cholinesterase activity in frog muscle.Neuropharmacology 14:791\u2013800 (1975).","journal-title":"Neuropharmacology"},{"key":"BF02353516_CR37","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/0006-8993(86)90768-7","volume":"375","author":"N. T. Slater","year":"1986","unstructured":"N. T. Slater, M. Filbert, and D. O. Carpenter. Multiple interactions of anticholinesterases with Aplysia acetylcholine responses.Brain Res. 375:407\u2013412 (1986).","journal-title":"Brain Res."},{"key":"BF02353516_CR38","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1097\/00000542-199003000-00018","volume":"72","author":"R. E. Wachtel","year":"1990","unstructured":"R. E. Wachtel. Comparison of anticholesterases and their effects on acetylcholineactivated ion channels.Anesthesiology 72:496\u2013503 (1990).","journal-title":"Anesthesiology"},{"key":"BF02353516_CR39","first-page":"92","volume":"25","author":"G. J. Pascuzzo","year":"1984","unstructured":"G. J. Pascuzzo, A. Akaike, M. A. Maleque, K. P. Shaw, R. S. Aronstam, D. L. Rickett, and E. X. Albuquerque. The nature of the interactions of pyridostigmine with the nicotinic acetylcholine receptor-ionic channel complex. I. Agonist, desensitizing, and binding properties.Mol. Pharmacol. 25:92\u2013101 (1984).","journal-title":"Mol. Pharmacol."},{"key":"BF02353516_CR40","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0378-4347(00)81693-X","volume":"183","author":"M. G. M. Ruyter De","year":"1980","unstructured":"M. G. M. De Ruyter and R. Cronnelly. Reversed-phase, ion-pair liquid chromatography of quaternary ammonium compounds. Determination of pyridostigmine, neostigmine and edrophonium in biological fluids.J. Chromatog. 183:193\u2013201 (1980).","journal-title":"J. Chromatog."},{"key":"BF02353516_CR41","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1248\/bpb1978.4.879","volume":"4","author":"K. Yamaoka","year":"1981","unstructured":"K. Yamaoka, Y. Tanigawara, T. Nakagawa, and T. Uno. A pharmacokinetic analysis program (MULTI) for microcomputer.J. Pharmacobiodyn. 4:879\u2013885 (1981).","journal-title":"J. Pharmacobiodyn."},{"key":"BF02353516_CR42","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1248\/bpb1978.6.595","volume":"6","author":"K. Yamaoka","year":"1983","unstructured":"K. Yamaoka and T. Nakagawa. A nonlinear least squares program based on differential equations, MULTI(RUNGE), for microcomputers.J. Pharmacobiodyn. 6:595\u2013606 (1983).","journal-title":"J. Pharmacobiodyn."},{"key":"BF02353516_CR43","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/0006-2944(74)90029-5","volume":"10","author":"S. A. Seifert","year":"1974","unstructured":"S. A. Seifert and M. E. Eldefrawi. Affinity of myasthenia drugs to acetylcholinesterase and acetylcholine receptor.Biochem. Med. 10:258\u2013265 (1974).","journal-title":"Biochem. Med."},{"key":"BF02353516_CR44","first-page":"937","volume":"41","author":"A. S. Hodge","year":"1992","unstructured":"A. S. Hodge, D. R. Humphrey, and T. L. Rosenbery. Ambenonium is a rapidly reversible noncovalent inhibitor of acetylcholinesterase, with one of the highest known affinities.Mol. Pharmacol. 41:937\u2013942 (1992).","journal-title":"Mol. Pharmacol."},{"key":"BF02353516_CR45","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1097\/00000542-198906000-00006","volume":"70","author":"A. F. Kopman","year":"1989","unstructured":"A. F. Kopman. Pancuronium, gallamine and d-tubocurarine compared: Is speed of onset inversely related to drug potency?Anesthesiology 70:915\u2013920 (1989).","journal-title":"Anesthesiology"},{"key":"BF02353516_CR46","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/BF01062962","volume":"19","author":"F. Donati","year":"1991","unstructured":"F. Donati and C. Meistelman. A kinetic-dynamic model to explain the relationship between high potency and slow onset time for neuromuscular blocking drugs.J. Pharmacokin. Biopharm. 19:537\u2013552 (1991).","journal-title":"J. Pharmacokin. Biopharm."},{"key":"BF02353516_CR47","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1097\/00000542-199208000-00019","volume":"77","author":"J. C. L. Min","year":"1992","unstructured":"J. C. L. Min, I. Bekavac, M. I. Glavinovic, F. Donati, and D. R. Bevan. Iontophoretic study of speed of action of various muscle relaxants.Anesthesiology 77:351\u2013356 (1992).","journal-title":"Anesthesiology"},{"key":"BF02353516_CR48","first-page":"1181","volume":"265","author":"M. I. Glavinovic","year":"1992","unstructured":"M. I. Glavinovic, J. C. L. Min, L. Kapural, F. Donati, and D. R. Bevan. Speed of action of various muscle relaxants at the neuromuscular junction binding vs. buffering hypothesis.J. Pharmacol. Exp. Ther. 265:1181\u20131186 (1992).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"BF02353516_CR49","unstructured":"T. P. Kenakin and D. Beek. Self-cancellation of drug properties as a mode of organ selectivity: The antimuscarinic effects of ambenonium.J. Pharmacol. Exp. Ther. 732\u2013740 (1985)."},{"key":"BF02353516_CR50","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1113\/jphysiol.1979.sp012917","volume":"294","author":"C. J. Duncan","year":"1979","unstructured":"C. J. Duncan and S. J. Publicover. Inhibitory effects of cholinergic agents on the release of transmitter at the frog neuromuscular junction.J. Physiol. 294:91\u2013103 (1979).","journal-title":"J. Physiol."},{"key":"BF02353516_CR51","first-page":"553","volume":"8","author":"R. J. Anderson","year":"1987","unstructured":"R. J. Anderson. Effect of pyridostigmine on tetanic contracture of innervated and denervated rat skeletal muscle.Neurotoxicology 8:553\u2013560 (1987).","journal-title":"Neurotoxicology"},{"key":"BF02353516_CR52","first-page":"229","volume":"36","author":"M. Fujii","year":"1982","unstructured":"M. Fujii and T. Namba. Inhibition of human motor endplate cholinesterase by anticholinesterase compounds.Acta Med. Okayama 36:229\u2013232 (1982).","journal-title":"Acta Med. Okayama"},{"key":"BF02353516_CR53","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/clpt.1985.179","volume":"38","author":"M. J. Chow","year":"1985","unstructured":"M. J. Chow, J. J. Ambre, T. I. Ruo, A. J. Atkinson, D. J. Bowsher, and M. W. Fischman. Kinetics of cocaine distribution, elimination, and chronotropic effects.Clin. Pharmacol. Ther. 38:318\u2013324 (1985).","journal-title":"Clin. Pharmacol. Ther."},{"key":"BF02353516_CR54","first-page":"231","volume":"244","author":"H. C. Porchet","year":"1988","unstructured":"H. C. Porchet, N. L. Benowitz, and L. B. Sheiner. Pharmacodynamic model of tolerance: Application to nicotine.J. Pharmacol. Exp. Ther. 244:231\u2013244 (1988).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"BF02353516_CR55","first-page":"447","volume":"233","author":"M. M. Hammarlund","year":"1985","unstructured":"M. M. Hammarlund, B. O. Odlind, and L. K. Paalzow. Acute tolerance to furosemide diuresis in humans. Pharmacokinetic-pharmacodynamic modeling.J. Pharmacol. Exp. Ther. 233:447\u2013453 (1985).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"BF02353516_CR56","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/BF01080875","volume":"19","author":"D. Verotta","year":"1991","unstructured":"D. Verotta, J. Kitts, R. Rodriguez, J. Coldwell, R. D. Miller, and L. B. Sheiner. Reversal of neuromuscular blockade in humans by neostigmine and edrophonium: A mathematical model.J. Pharmacokin. Biopharm. 19:713\u2013729 (1991).","journal-title":"J. Pharmacokin. Biopharm."},{"key":"BF02353516_CR57","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/00000542-198105000-00009","volume":"54","author":"R. B. Morris","year":"1981","unstructured":"R. B. Morris, R. Cronnelly, R. D. Miller, D. R. Stanski, and M. R. Fahey. Pharmacokinetics of edrophonium and neostigmine when antagonizing d-tubocurarine neuromuscular blockade in man.Anesthesiology 54:399\u2013402 (1981).","journal-title":"Anesthesiology"}],"container-title":["Journal of Pharmacokinetics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF02353516.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF02353516\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF02353516","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,6]],"date-time":"2023-05-06T23:23:23Z","timestamp":1683415403000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF02353516"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1996,8]]},"references-count":57,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1996,8]]}},"alternative-id":["BF02353516"],"URL":"https:\/\/doi.org\/10.1007\/bf02353516","relation":{},"ISSN":["0090-466X"],"issn-type":[{"value":"0090-466X","type":"print"}],"subject":[],"published":{"date-parts":[[1996,8]]}}}